Littérature scientifique sur le sujet « Alfuzosine »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Alfuzosine ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Alfuzosine"
Marini, F., F. Martino, V. Alfano, G. P. Vancini et R. Valente. « Trattamento Sintomatico Dell'Ipertrofia Prostatica Benigna Con Alfuzosine ». Urologia Journal 57, no 1 (février 1990) : 29–34. http://dx.doi.org/10.1177/039156039005700105.
Texte intégralGuerre, A., D. M. Hartl et P. Katz. « Les Alpha-1-Bloquants (alfuzosine) en pathologie salivaire obstructive ». Revue de Stomatologie et de Chirurgie Maxillo-faciale 111, no 3 (juin 2010) : 135–39. http://dx.doi.org/10.1016/j.stomax.2010.04.002.
Texte intégralde Goede, A. « Alfuzosine geeft geen vermindering van symptomen van chronische prostatitis-chronische bekkenpijnsyndroom ». Medisch-Farmaceutische Mededelingen 47, no 4 (avril 2009) : 50–51. http://dx.doi.org/10.1007/bf03079915.
Texte intégralCarbin, B. E., P. Bauer, M. Friskand et D. Moyse. « EFFICACY OF ALFUZOSINE (an α1-adrenoreceptor blocking drug) IN BENIGN HYPERPLASIA OF THE PROSTATE ». Scandinavian Journal of Urology and Nephrology 25, sup138 (1 janvier 1991) : 73–75. http://dx.doi.org/10.1080/21681805.1991.12068870.
Texte intégralEl, Sheikh, Nahla Esmail, Ayman Gouda et Walid Basset. « Extractive spectrophotometric determination of some α-adrenergic-antagonists in pure forms and in pharmaceutical formulations ». Chemical Industry and Chemical Engineering Quarterly 18, no 2 (2012) : 179–91. http://dx.doi.org/10.2298/ciceq110917060e.
Texte intégralMari, Andrea, Alessandro Antonelli, Luca Cindolo, Ferdinando Fusco, Andrea Minervini et Cosimo De Nunzio. « Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms : a systematic review of the literature and narrative synthesis ». Therapeutic Advances in Urology 13 (janvier 2021) : 175628722199328. http://dx.doi.org/10.1177/1756287221993283.
Texte intégralSiddique, Md Saifuddin Ahmed, Sharmin Nahar Bashar, Mohammed Monowar UL Haque, Md Abdul Latif et Farid Uddin Ahmed. « Comparison Between Alfuzosin Monotherapy And Combination of Alfuzosin With Finasteride In Symptomatic Benign Prostatic Hyperplasia ». Journal of Chittagong Medical College Teachers' Association 28, no 2 (10 février 2018) : 75–80. http://dx.doi.org/10.3329/jcmcta.v28i2.62426.
Texte intégralVamsi Krishna, M., et D. Gowri Sankar. « Optimization and Validation of Quantitative Spectrophotometric Methods for the Determination of Alfuzosin in Pharmaceutical Formulations ». E-Journal of Chemistry 4, no 3 (2007) : 397–407. http://dx.doi.org/10.1155/2007/912762.
Texte intégralShrestha, Santosh, DB Adhikari, A. Gurung, S. Pradhan, NV Gurung, A. Acharya, D. Shrestha et al. « Role of Alfuzosin in Ureteral Stent Related Urinary Symptoms Score : A Comparative Study ». Journal of Gandaki Medical College-Nepal 10, no 1 (1 août 2017) : 28–30. http://dx.doi.org/10.3126/jgmcn.v10i1.17912.
Texte intégral&NA;. « Alfuzosin ». Reactions Weekly &NA;, no 729 (novembre 1998) : 6. http://dx.doi.org/10.2165/00128415-199807290-00015.
Texte intégralThèses sur le sujet "Alfuzosine"
Ah-hot, Michel. « Effest de l'alfuzosine par voie intraveineuse sur l'hémodynamique de l'insuffisant cardiaque ». Paris 5, Cochin, 1988. http://www.theses.fr/1988PA05C031.
Texte intégralLiu, Quan. « Development of a novel gastro-retentive delivery system using alfuzosin HCl as a model drug ». Diss., Temple University Libraries, 2010. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/80170.
Texte intégralPh.D.
The objectives of this project encompass the design and development of a drug delivery system to continuously deliver therapeutic agents from the stomach to the proximal region of the intestine. The delivery system designed would have sufficient gastric residence time together with near zero-order release kinetics. The physicochemical properties pertaining to the formulation development of the model drug (alfuzosin HCl) were evaluated. Excipients were selected based on the studies of their physicochemical properties and compatibility with the active ingredient. Gastro-retentive dosage forms have been the topic of interest in recent years as a practical approach in drug deliveries to the upper GI tract or for release prolongation and absorption. These dosage forms are particularly suitable for drugs that have local effects on the gastric mucosa in the stomach. Other candidates include drugs that are likely to be absorbed in the upper small intestine, or drugs that are unstable in basic environment of distal intestine and colon or those with low solubility at elevated pH conditions (i.e. weak bases). To develop a gastro-retentive delivery system the following steps were taken. First, to investigate the possible incompatibility issues between the model drug and excipients to be used for the delivery system. Stability and physicochemical properties of the active agent and its mixture with excipients were studied using analytical techniques such as Raman spectroscopy and Differential scanning calorimetry (DSC). No incompatibility issues were detected. Second, Kollidon SR as a relatively new release-rate controlling polymer was incorporated in the final formulation. For solid dosage form the ability of the final powder mix to flow well during manufacturing and the intrinsic characteristics that make it compressible are critical. The in-depth compaction study of Kollidon SR was assessed with the help of a compaction simulator. The flowability, swelling and erosion behavior together with release-rate retarding properties of Kollidon SR were also assessed. The final oral delivery system was based on Kollidon SR and Polyethylene Oxide (PEO) 303 as a monolithic matrix system. The noneffervescent monolithic matrix was made by direct compression. In vitro evaluation of the designed system released the active content in a near zero manner. The dosage form was bouyant in pH 2.0 acidic buffer with no floatation lag time which minimizes the possibility of early gastric emptying.
Lee, Wei-Yang, et 李維揚. « Preparation and release studies of alfuzosin matrix and matrix-coating system ». Thesis, 2009. http://ndltd.ncl.edu.tw/handle/3mhp48.
Texte intégral嘉南藥理科技大學
藥物科技研究所
97
Three common oral controlled delivery systems including matrix, reservoir, and osmotic pump system are often used in the pharmaceutical field. The aim of this study is to investigate the performance and mechanism of different formulations of alfuzosin hydrochloride using matrix and matrix-coating system. Different excipients such as water swellable polymeric matrices have found broad application in controlled release system, and diffusion often controls the rate of drug release from the system. Therefore, in order to control drug release, characterization of the effects of the polymer blends and polymer swelling on drug release diffusion is crucial. In the present study, direct compression method was utilized to prepare matrix tablets. The amounts of hydroxyl propyl methyl cellulose (HPMC) in matrix and various amount of hydrophilic / hydrophobic polymers in matrix -coating membrane were studied to assess drug release characteristics. The coating membrane used were percentage of 3% and 5%. Drug permeability and mechanical properties of polymer membrane with different composition were determined. Dissolution tests were performed according to the USP paddle method (900 ml medium, 37 ± 0.5℃ and 100 rpm). For matrix tablets, the results indicate that drug release rates can be decreased by increasing amount of HPMC. Swelling results are also consistent with drug release results. Higher swelling and less erosion were observed for tablet with higher amount of HPMC. For matrix-coating systems, the results indicate that drug release rates can be decreased by increasing amount of hydrophobic polymers in polymer blend and coating percentage. The results demonstrate that controlled release of alfuzosin hydrochloride is feasible using matrix and matrix-coating system.
Chang, Shu-chen, et 張素真. « Evaluation of the combined use of saw palmetto and alfuzosin in the treatment of benign prostatic hyperplasia ». Thesis, 2006. http://ndltd.ncl.edu.tw/handle/29rynz.
Texte intégral南華大學
自然醫學研究所
95
This study aims to investigate the clinical effects of a phytotherapeutic agent saw palmetto, the drug Alfuzosin, both singly and jointly in patients experiencing lower urinary tract symptoms (LUTS) who were also diagnosed with benign prostatic hyperplasia (BPH). A total of 28 patients diagnosed with BPH and met the study criteria were divided into three groups based on the severity of their symptoms. Those of mild severity (n=10) were asked to take saw palmetto extract at 320mg per day (Group P) and those of moderate severity (n=10) were asked to take alfuzosin at 10 mg per day (Group A). Those of greatest severity (n=8) were asked to take both saw palmetto extract and alfuzosin (Group PA). Serum prostate specific antigen (PSA), maximal flow rate (Qmax), prostate volume (PV), and the International Prostate Symptom Score (IPSS) were obtained at the baseline and at the end of the three-month intervention. Results indicated that PV decreased by 4.8±8.2cc and 3.8±1.8cc in the Group P and Group PA and the reduction was significantly lowered than that in the Group A (p=0.032). In the IPSS score, the reduction in Group PA (-7.6±3.0) and Group A (-4.3±1.3) were significantly greater than that of Group P (-3.1±3.0) (p=0.003). The reduction in score was attributed by the changes in the obstructive symptoms (p=0.005) and three of its four items, namely, incomplete emptying (p=0.029), intermittency (p=0.032), and weak stream (p=0.018). The reduction in Group P was not significantly differed from that of Group A and that Group PA was not significantly differed from that of Group A. In conclusion, this study found that saw palmetto extract can improve certain lower urinary tract symptoms, particularly those of obstruction in nature, associated with BPH. The combined effect of saw palmetto and alfuzosin appeared to be more significant than when these agents were used singly. Future clinical studies in this area may provide patients with BPH additional therapeutical choices.
Chapitres de livres sur le sujet "Alfuzosine"
Zwaveling, J. « Waarom moet tamsulosine tijdens het ontbijt en waarom alfuzosine tijdens het avondeten worden ingenomen ? » Dans Vademecum permanente nascholing huisartsen, 3332–33. Houten : Bohn Stafleu van Loghum, 2006. http://dx.doi.org/10.1007/978-90-313-8808-0_1738.
Texte intégral« Alfuzosin ». Dans Meyler's Side Effects of Drugs : The International Encyclopedia of Adverse Drug Reactions and Interactions, 74–75. Elsevier, 2006. http://dx.doi.org/10.1016/b0-44-451005-2/00400-9.
Texte intégral« ALFUZOSIN ». Dans Litt's Drug Eruptions and Reactions Manual, 24. CRC Press, 2014. http://dx.doi.org/10.1201/b15347-8.
Texte intégral« Alfuzosin. » Dans Drugs Handbook 2012–2013. Bloomsbury Academic, 2011. http://dx.doi.org/10.5040/9781350363595.art-43.
Texte intégralMichel, Martin C. « Alfuzosin ». Dans xPharm : The Comprehensive Pharmacology Reference, 1–4. Elsevier, 2007. http://dx.doi.org/10.1016/b978-008055232-3.63088-0.
Texte intégral« Alfuzosin ». Dans Meyler's Side Effects of Drugs, 142–43. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-444-53717-1.00244-4.
Texte intégral« Alfuzosin ». Dans Checkliste Arzneimittel A–Z, sous la direction de Detlev Schneider et Frank Richling. Stuttgart : Georg Thieme Verlag, 2013. http://dx.doi.org/10.1055/b-0034-82206.
Texte intégral« Alfuzosin ». Dans Hale’s Medications & ; Mothers’ Milk™ 2019. New York, NY : Springer Publishing Company, 2018. http://dx.doi.org/10.1891/9780826150356.0023.
Texte intégral« Alfuzosin A Jardin ». Dans Therapeutic Treatment for Benign Prostatic Hyperplasia, 127–46. CRC Press, 2005. http://dx.doi.org/10.1201/b14479-11.
Texte intégralMahapatra, Abikesh Prasada Kumar, Sonia P. Nagvenkar et Rajashree Gude. « Studying Formulation and Physicochemical Characterization of Buccal Mucoadhesive Films Containing Alfuzosin Hydrochloride ». Dans Technological Innovation in Pharmaceutical Research Vol. 1, 75–88. Book Publisher International (a part of SCIENCEDOMAIN International), 2021. http://dx.doi.org/10.9734/bpi/tipr/v1/2271e.
Texte intégralActes de conférences sur le sujet "Alfuzosine"
Mamina, O., V. Kabachny et N. Bondarenko. « ANALYSIS OF ALFUZOSIN BY HPLC METHOD ». Dans DÉBATS SCIENTIFIQUES ET ORIENTATIONS PROSPECTIVES DU DÉVELOPPEMENT SCIENTIFIQUE. European Scientific Platform, 2021. http://dx.doi.org/10.36074/logos-05.02.2021.v6.29.
Texte intégralPhilip, C., et A. Glanard. « DI-067 Retrospective study of alfuzosin 10 mg prescriptions ». Dans 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.314.
Texte intégralChurakov, A. A. « КОМБИНИРОВАННАЯ ЭРИКСОНОВСКАЯ ПСИХОТЕРАПИЯ В КОМПЛЕКСНОМ ЛЕЧЕНИИ КОМОРБИДНОГО ПАЦИЕНТА ». Dans ПЕРВЫЙ МЕЖКОНТИНЕНТАЛЬНЫЙ ЭКСТЕРРИТОРИАЛЬНЫЙ КОНГРЕСС «ПЛАНЕТА ПСИХОТЕРАПИИ 2022 : ДЕТИ. СЕМЬЯ. ОБЩЕСТВО. БУДУЩЕЕ». Crossref, 2022. http://dx.doi.org/10.54775/ppl.2022.78.49.001.
Texte intégral